Citations

Clear

367 citation(s) found for "Du, Pan".

Abstract 55: Trans-facial Minimal-Dissection External Mandibular Distraction Osteogenesis for Neonatal Airway Obstruction from Pierre Robin Sequence
Massary, Dominic, Lor, Lyfong S., Jahanpanah, Shayan, Pan, Brian S. , Gordon, Christopher B., Babiker, Haithem Elhadi, Oliver, Jeremie D. , Runyan, Christopher Michael

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 29, 2019 | Volume: 7 | Issue: 4S | Pages: 39-39

10.1097/01.gox.0000558329.55821.c8 Get It

Methodological consensus on clinical proton MRS of the brain: Review and recommendations
Wilson, Martin , Andronesi, Ovidiu C. , Barker, Peter B. , Bartha, Robert , Bizzi, Alberto , Bolan, Patrick J. , Cudalbu, Cristina , Dydak, Ulrike , Emir, Uzay E. , González, R. Gilberto , Gruber, Stephan , Gupta, Rakesh K. , Henning, A , Hetherington, Hoby P. , Hüppi, Petra S. , Hurd, Ralph E. , Kantarci, Kejal , Kauppinen, Risto A. , Klomp, Dennis W. J. , Kreis, Roland , Kruiskamp, Marijn J., Leach, Martin O. , Lin, Alexander , Luijten, Peter R. , Marjańska, Małgorzata , Meyerhoff, Dieter J. , Mountford, Carolyn E. , Mullins, Paul G. , Murdoch, James B. , Nelson, Sarah J. , Noeske, Ralph , Öz, Gülin , Pan, Julie W., Poptani, Harish , Posse, Stefan , Ratai, Eva‐Maria , Salibi, Nouha , Scheenen, Tom W. J. , Soher, Brian J. , Tkáč, Ivan , Vigneron, Daniel B. , Howe, Franklyn A. , Choi, In‐Young , Kreis, Roland , Maudsley, Andrew A , Howe, Franklyn A , Öz, Gülin , Marjańska, Małgorzata , Kantarci, Kejal , Brindle, Kevin Michael , Choi, In‐Young, Gruetter, Rolf , Heerschap, Arend , Peet, Andrew C. , Smith, Ian C. P.

Mayo Clinic

Magnetic Resonance in Medicine | March 28, 2019 | Volume: 82 | Issue: 2 | Pages: 527-550

10.1002/mrm.27742 | PMID 30919510 Get It

Proton MRS (1H MRS) provides noninvasive, quantitative metabolite profiles of tissue and has been shown to aid the clinical management of several brain diseases. Although most modern clinical MR scanners support MRS capabilities, routine use is largely restricted to specialized centers with good access to MR research support. Widespread adoption has been slow for several reasons, and technical challenges toward obtaining reliable good‐quality results have been identified as a contributing factor. Considerable progress has been made by the research community to address many of these challenges, and in this paper a consensus is presented on deficiencies in widely available MRS methodology and validated improvements that are currently in routine use at several clinical research institutions. In particular, the localization error for the PRESS localization sequence was found to be unacceptably high at 3 T, and use of the semi‐adiabatic localization by adiabatic selective refocusing sequence is a recommended solution. Incorporation of simulated metabolite basis sets into analysis routines is recommended for reliably capturing the full spectral detail available from short TE acquisitions. In addition, the importance of achieving a highly homogenous static magnetic field (B0) in the acquisition region is emphasized, and the limitations of current methods and hardware are discussed. Most recommendations require only software improvements, greatly enhancing the capabilities of clinical MRS on existing hardware. Implementation of these recommendations should strengthen current clinical applications and advance progress toward developing and validating new MRS biomarkers for clinical use.
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Peng, David H. , Kundu, Samrat T. , Fradette, Jared J. , Diao, Lixia , Tong, Pan, Byers, Lauren A. , Wang, Jing , Canales, Jaime Rodriguez, Villalobos, Pamela, Mino, Barbara , Yang, Yanan , Minelli, Rosalba, Peoples, Michael , Bristow, Christopher A. , Heffernan, Timothy P. , Carugo, Alessandro , Wistuba, Ignacio I. , Peoples, Michael D , Gibbons, Don L , Yang, Yanan

Mayo Clinic

Science Translational Medicine | March 13, 2019 | Volume: 11 | Issue: 483 | Pages: No page available

10.1126/scitranslmed.aaq1238 | PMID 30867319 Get It

Suppression of ZEB1 through miR-200 expression or HDAC inhibition with mocetinostat sensitizes resistant KRAS mutant lung cancers to MEK inhibition.
Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer.
Yadav, Siddhartha , Tan, Winston , Wang, Amy , Montesinos, Carlos, Wong, Calvin, Jia, Shidong , Yu, Jianjun , Yadav, Siddhartha , Kohli, Manish , Riaz, Irbaz Bin , Zheng, Tiantian , Du, Peter Pan

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 242-242

10.1200/jco.2019.37.7_suppl.242 Get It

242 Background: We evaluated plasma cell free based genomic aberrations for prognosticating survival of newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) patients (pts). Methods: Plasma was collected from mHSPC pts enrolled between 2009-2014. Platelet poor plasma (PPP) fractions were processed uniformly and cell free DNA (cfDNA) extracted using Qiagen kits. Pts were followed after initiating hormonal therapy until death. Next Gen Sequencing (NGS) of cfDNA was performed using Illumina HiSeq X for a preselected panel of 128 genes (PredicineDDR-77 cancer driver genes; 29 genes in BRCA-FA homologous recombination deficiency (HRD) pathway; 22 DNA damage repair pathway genes). Statistical analyses of plasma genome based aberrations with overall survival (OS) were performed in R 3.5.1. Cox proportional-hazard models were used for survival analysis. Results: An average of 2.5 ml PPP from 99 pts yielded a median of 10.5 ng (range: 2.8-702) cfDNA per sample. 15/99 pt samples with a yield < 5 ng were excluded from sequencing; 9/99 samples failed NGS. Median follow-up time was 80.2 months (mths) (Range: 74.7, 87]); median OS was 69.1 mths (range: 54,NR). 29 pts with full NGS data had high volume metastatic disease. cfDNA yield correlated with metastatic volume (P = 0.01). Univariate analysis revealed both variables prognostic for OS (Metastatic volume: log-rank P=0.01, HR=2.1, 95% CI: 1.1-3.8; cfDNA yield: P =0.04, HR = 1.3, 95% CI: 1.03-1.7). Multivariate regression showed prognostic value of cfDNA yield remained independent of metastatic volume (P = 0.03, HR = 1.34, 95% CI: 1.02-1.76). 54/67 samples with NGS data had at least one mutation/copy number variation detected. Top mutated genes included TP53 (N=18), ATM (N=9), CHEK2 (N=7), FANCM (N=6), RB1 (N=6), BRCA2 (N=5), PIK3CA (N=4) and 37/67 pts harbored 1≥ variant in HDR pathways. These pts had a shorter survival (median: 58.6 mths) (P=0.04, HR= 2.28, 95% CI: 1.01-5.18) and pts with ATM mutations did significantly worse (median survival: 47.4 mths) (HR=4.03, P=0.0005, 95% CI: 1.73-9.37). Conclusions: Plasma cfDNA yield is prognostic for survival in newly diagnosed mHSPC state and presence of HRD pathway genomic aberrations in plasma cfDNA are associated with poor survival.
Percutaneous Pedicle Screw Fixation Alone Versus Debridement and Fusion Surgery for the Treatment of Early Spinal Tuberculosis: A Retrospective Cohort Study
Guo, Song , Zhu, Kai , Zhang, Shuya , Yang, Mingjie , Yan, Meijun , Li, Xinhua , Pan, Jie , Li, Lijun , Wang, Zhigang , Tan, Jun , Ma, Bin

Mayo Clinic

Medical Science Monitor | February 27, 2019 | Volume: 25 | Issue: No issue available | Pages: 1549-1557

10.12659/msm.912538 | PMID 30811378 Get It

Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide
Meems, Laura M.G., Andersen, Ingrid A., Pan, Shuchong, Harty, Gail J., Zheng, Ye , Harders, Gerald E., Ichiki, Tomoko , Heublein, Denise M., Sangaralingham, S. Jeson , Burnett, John C. , Harty, Gail, Ichiki, Tomoki, Iyer, Seethalakshmi R., McCormick, Daniel J., Chen, Yang , Iyer, Seethalakshmi , Sangaralingham, S. Jeson , McCormick, Daniel

Mayo Clinic

Hypertension | February 25, 2019 | Volume: 73 | Issue: 4 | Pages: 900-909

10.1161/hypertensionaha.118.12012 | PMID 30798663 Get It

Despite optimal current therapies, cardiovascular disease remains the leading cause for death worldwide. Importantly, advances in peptide engineering have accelerated the development of innovative therapeutics for diverse human disease states. Additionally, the advancement of bispecific therapeutics targeting >1 signaling pathway represents a highly innovative strategy for the treatment of cardiovascular disease. We, therefore, engineered a novel, designer peptide, which simultaneously targets the pGC-A (particulate guanylyl cyclase A) receptor and the MasR (Mas receptor), potentially representing an attractive cardiorenoprotective therapeutic for cardiovascular disease. We engineered a novel, bispecific receptor activator, NPA7, that represents the fusion of a 22-amino acid sequence of BNP (B-type natriuretic peptide; an endogenous ligand of pGC-A) with Ang 1–7 (angiotensin 1–7)—the 7-amino acid endogenous activator of MasR. We assessed NPA7’s dual receptor activating actions in vitro (second messenger production and receptor interaction). Further, we performed an intravenous peptide infusion comparison study in normal canines to study its biological actions in vivo, including in the presence of an MasR antagonist. Our in vivo and in vitro studies demonstrate the successful synthesis of NPA7 as a bispecific receptor activator targeting pGC-A and MasR. In normal canines, NPA7 possesses enhanced natriuretic, diuretic, systemic, and renal vasorelaxing and cardiac unloading properties. Importantly, NPA7’s actions are superior to that of the individual native pGC-A or MasR ligands. These studies advance NPA7 as a novel, bispecific designer peptide with potential cardiorenal therapeutic benefit for the treatment of cardiovascular disease, such as hypertension and heart failure.
MCAM abnormal expression and clinical outcome associations are highly cancer dependent as revealed through pan-cancer analysis
An, Yunxia, Wei, Nan , Cheng, Xiangsong, Li, Ying , Liu, Haiyang , Xu, Zhiwei , Zhang, Xiaoju , Sun, Zhifu

Mayo Clinic

Briefings in Bioinformatics | February 18, 2019 | Volume: 21 | Issue: 2 | Pages: 709-718

10.1093/bib/bbz019 | PMID 30815677 Get It

Abstract MCAM (CD146) is a cell surface adhesion molecule that has been reported to promote cancer development, progression and metastasis and is considered as a potential tumor biomarker and therapeutic target. However, inconsistent reports exist, and its clinical value is yet to be confirmed. Here we took advantage of several large genomic data collections (Genotype-Tissue Expression, The Cancer Genome Atlas and Cancer Cell Line Encyclopedia) and comprehensively analyzed MCAM expression in thousands of normal and cancer samples and cell lines along with their clinical phenotypes and drug response information. Our results show that MCAM is very highly expressed in large vessel tissues while majority of tissues have low or minimal expression. Its expression is dramatically increased in a few tumors but significantly decreased in most other tumors relative to their pairing normal tissues. Increased MCAM expression is associated with a higher tumor stage and worse patient survival for some less common tumors but not for major ones. Higher MCAM expression in primary tumors may be complicated by tumor-associated or normal stromal blood vessels yet its significance may differ from the one from cancer cells. MCAM expression is weakly associated with the response to a few small molecular drugs and the association with targeted anti-BRAF agents suggests its involvement in that pathway which warrants further investigation.
Impaired Postural Control and Altered Sensory Organization During Quiet Stance Following Neurotoxic Chemotherapy: A Preliminary Study
Monfort, Scott M. , Pan, Xueliang , Loprinzi, Charles L. , Lustberg, Maryam B. , Chaudhari, Ajit M.W. , Lustberg, Maryam

Mayo Clinic

Integrative Cancer Therapies | February 11, 2019 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/1534735419828823 | PMID 30741022 Get It

Individuals diagnosed with chemotherapy-induced peripheral neuropathy (CIPN) demonstrate impaired balance and carry an increased risk of falling. However, prior investigations of postural instability have only compared these individuals against healthy controls, limiting the understanding of impairments associated with CIPN. Therefore, the purpose of this study was to better isolate postural control impairments that are associated with CIPN. Twenty cancer survivors previously diagnosed with breast or colorectal cancer participated. Participants were separated into 3 groups: no prior chemotherapy exposure (CON, n = 6), and recent treatment with taxane- or oxaliplatin-based chemotherapy with no/mild symptoms of CIPN (−CIPN, n = 8) or moderate/severe symptoms of CIPN (+CIPN, n = 6). Postural control was assessed by measuring center of pressure during standing balance conditions that systematically interfered with somatosensory, visual, and/or vestibular information. The presence of CIPN sensory symptoms was associated with impaired postural control, particularly during eyes-closed balance conditions ( P < .05). Additionally, medial-lateral postural instability was more pronounced in the +CIPN group compared with the −CIPN group and CON participants ( P < .05). Greater postural instability during eyes-closed balance in individuals with CIPN is consistent with impaired peripheral sensation. Balance impairments in cancer survivors with CIPN demonstrate the unique challenges in this population and motivate the need for targeted efforts to mitigate postural control deficits that have previously been associated with fall risk.
FoxO Transcription Factors Are Critical Regulators of Diabetes-Related Muscle Atrophy
O’Neill, Brian T. , Penniman, Christie M., Krumpoch, Megan, Beltran, Pablo A. Suarez, Klaus, Katherine A. , Poro, Kennedy, Pan, Hui , Klaus, Katherine, Kahn, C Ronald , Bhardwaj, Gourav , Li, Mengyao , Pan, Hui , Dreyfuss, Jonathan M. , Nair, K. Sreekumaran

Mayo Clinic

Diabetes | December 6, 2018 | Volume: 68 | Issue: 3 | Pages: 556-570

10.2337/db18-0416 | PMID 30523026 Get It

Insulin deficiency and uncontrolled diabetes lead to a catabolic state with decreased muscle strength, contributing to disease-related morbidity. FoxO transcription factors are suppressed by insulin and thus are key mediators of insulin action. To study their role in diabetic muscle wasting, we created mice with muscle-specific triple knockout of FoxO1/3/4 and induced diabetes in these M-FoxO-TKO mice with streptozotocin (STZ). Muscle mass and myofiber area were decreased 20–30% in STZ-Diabetes mice due to increased ubiquitin-proteasome degradation and autophagy alterations, characterized by increased LC3-containing vesicles, and elevated levels of phosphorylated ULK1 and LC3-II. Both the muscle loss and markers of increased degradation/autophagy were completely prevented in STZ FoxO-TKO mice. Transcriptomic analyses revealed FoxO-dependent increases in ubiquitin-mediated proteolysis pathways in STZ-Diabetes, including regulation of Fbxo32 (Atrogin1), Trim63 (MuRF1), Bnip3L, and Gabarapl. These same genes were increased 1.4- to 3.3-fold in muscle from humans with type 1 diabetes after short-term insulin deprivation. Thus, FoxO-regulated genes play a rate-limiting role in increased protein degradation and muscle atrophy in insulin-deficient diabetes.